Journal
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 10, Issue 9, Pages 1047-+Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2012.03.016
Keywords
Hepatitis B Virus; Antiviral Therapy; Nucleos(t)ide Analogue
Categories
Funding
- Gilead
- Bristol-Myers Squibb
- Novartis
- Idenix
- Roche
- Schering Plough
- Merck
- Intercept
- Abbott
- Pharmasset
- Mochida
- Conatus
- Vertex
Ask authors/readers for more resources
There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available